Iron replacement therapy in cancer-related anemia
- 15 May 2011
- journal article
- review article
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 68 (10_Supplem) , S4-S14
Abstract
Purpose The incidence, etiology, and management of cancer-related anemia is reviewed and the role of i.v. iron therapy in its treatment is described. Summary Between 30% and 90% of patients with cancer develop anemia due to direct effects of the disease, its treatment, underlying nutritional deficiencies, and the inflammation that characterizes chronic disease. Although the use of erythropoiesis-stimulating agents (ESAs) increases hemoglobin levels and decreases the need for transfusions, up to 50% of patients do not to respond to these drugs, usually due to the presence of absolute or functional iron deficiency. Multiple clinical trials have demonstrated that i.v. iron supplementation in patients with cancer-related anemia improves the response rate to ESAs, reduces the time to target hemoglobin levels, decreases ESA requirements, reduces costs, and is more efficacious than oral iron. These benefits are seen without increased toxicity. Nonetheless, i.v. iron remains underused in patients with cancer, partly due to misinformation and misinterpretation of the clinical nature of adverse events. Conclusion Intravenous iron is underutilized in patients with cancer-related anemia. Based on published evidence, i.v. iron supplementation in patients with absolute or functional iron deficiency can improve patient responses to ESAs and reduce ESA requirements and may also reduce the need for transfusions and improve quality of life.Keywords
This publication has 48 references indexed in Scilit:
- Intravenous iron: From anathema to standard of careAmerican Journal of Hematology, 2008
- Anaemia of cancer: an overview of mechanisms involved in its pathogenesisMedical Oncology, 2007
- Clinical update: intravenous iron for anaemiaThe Lancet, 2007
- Anemia in patients with cancer: Incidence, causes, impact, management, and use of treatment guidelines and protocolsAmerican Journal of Health-System Pharmacy, 2007
- Iron or vitamin B12 deficiency in anemic cancer patients prior to erythropoiesis-stimulating agent therapyCommunity Oncology, 2007
- Hepcidin and Its Role in Regulating Systemic Iron MetabolismHematology-American Society Hematology Education Program, 2006
- Anaemia of Cancer: Impact on Patient Fatigue and Long-Term OutcomeOncology, 2005
- Anemia of Chronic DiseaseNew England Journal of Medicine, 2005
- Prevalence and outcomes of anemia in cancer: a systematic review of the literatureThe American Journal of Medicine, 2004
- Regulation of iron metabolism in the acute‐phase response: interferon γ and tumour necrosis factor α induce hypoferraemia, ferritin production and a decrease in circulating transferrin receptors in cancer patientsEuropean Journal of Clinical Investigation, 1998